| 產(chǎn)品編號 | bsm-41662M |
| 英文名稱 | Mouse Anti-Human VEGF165 antibody |
| 中文名稱 | 人血管內(nèi)皮生長因子單克隆抗體 |
| 別 名 | VEGF165; Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; Vegf; VEGFA; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF; VEGF A Precursor. |
| 研究領(lǐng)域 | 心血管 生長因子和激素 血管內(nèi)皮細胞 |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號 | 19F2 |
| 交叉反應(yīng) | (predicted: Human) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 18kDa |
| 細胞定位 | 分泌型蛋白 |
| 性 狀 | Liquid |
| 免 疫 原 | Recombinant human VEGF165 Protein: 27-191/191 |
| 亞 型 | IgG1 |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M PBS (pH7.4). |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF), is a signal protein produced by cells that stimulates the formation of blood vessels. To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). Function: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Subunit: Homodimer; disulfide-linked. Also found as heterodimer with PGF (By similarity). Subcellular Location: Secreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. Tissue Specificity : Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. DISEASE: Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Similarity: Belongs to the PDGF/VEGF growth factor family. SWISS: P15692 Gene ID: 7422 Database links: Entrez Gene: 7422 Human Entrez Gene: 22339 Mouse Omim: 192240 Human SwissProt: P15692 Human SwissProt: Q00731 Mouse Unigene: 73793 Human Unigene: 282184 Mouse Unigene: 1923 Rat |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Recombinant Human VEGF165 Protein at 500ng
Primary: Mouse Anti-VEGF165 Monoclonal Antibody at 1/1000 dilution (Cat.bsm-41662M)
Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution
Predicted band size: 21kD
Observed band size: 25kD
Measured by its binding ability in a indirect ELISA. Immobilized Human VEGF165, His Tag (Cat. bs-41613P) at 2 μg/mL (100 μL/well) can bind Anti-Human VEGF165 monoclonal antibody, the minimum detection concentration is 0.5ng/mL
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
